Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role

Abstract

The objective of this study was to determine the safety and tolerability of the immunomodulatory agent thalidomide as adjunct therapy in children with tuberculous meningitis. Children with stage 2 tuberculous meningitis received oral thalidomide for 28 days in a dose-escalating study, in addition to standard four-drug antituberculosis therapy, corticosteroids, and specific treatment of complications such as raised intracranial pressure. Clinical and laboratory evaluations were carried out. Fifteen patients (median age, 34 months) were enrolled. Thalidomide was administered via nasogastric tube in a dosage of 6 mg/kg/day, 12 mg/kg/day, or 24 mg/kg/day. The only adverse events possibly related to the study drug were transient skin rashes in two patients. Levels of tumor necrosis factor-α in the cerebrospinal fluid decreased markedly during thalidomide therapy. Clinical outcome and neurologic imaging showed greater improvement than that experienced with historical controls. Thalidomide appeared safe and well tolerated in children with stage 2 tuberculous meningitis and could have important anti-inflammatory effects. These promising results have led us to embark on a randomized, double-blind, placebo-controlled trial of the efficacy of thalidomide in tuberculous meningitis. (J Child Neurol 2000;15:497-503).

Get full access to this article

View all access options for this article.

References

National

Department of Health of South Africa: Notifiable medical conditions. Epidemiol

Comm 1996;23:1-2.

Donald PR , Cotton MF , Hendricks MK , et al: Pediatric meningitis in the Western Cape Province of South Africa . J Trop Pediatr 1996;42:256-261.

Deeny JE , Walker MJ , Kibel MA , et al: Tuberculous meningitis in children in the Western Cape. Epidemiology and outcome. S Afr Med J 1985;68:75-78.

Dastur DK , Lalitha VS : The many facets of neurotuberculosis: An epitome of neuropathology , in Zimmerman HM (ed): Progress in Neuropathology. New York, Grune & Stratton, 1973, pp 351-408.

Schoeman J. , Donald P. , Van Zyl L. , et al: Tuberculous hydrocephalus: Comparison of different treatments with regard to intracranial pressure, ventricular size and clinical outcome . Dev Med ChiLd Neurol 1991;33:396-405.

Schoeman JF , Van Zyl LE , Laubscher JA , Donald PR : Serial CT scanning in childhood tuberculous meningitis: Prognostic features in 198 cases. J Child Neurol 1995 ; 10:320-329.

Afghani B. , Lieberman JM : Paradoxical enlargement or development of intracranial tuberculomas during therapy: Case report and review. Clin Infect Dis 1994;19:1092—1099.

Schoeman JF , Van Zyl LE , Laubscher JA , Donald PR : Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis . Pediatrics 1997;99:226—231.

Donald PR , Schoeman JF , Beyers N. , et al: Concentrations of interferon γ, tumor necrosis factor α and interleukin 1β in the cerebrospinal fluid of children treated for tuberculous meningitis. Clin Infect Dis 1995 ;21:924—929.

10.

Moreira AL , Sampaio EP , Zmuidzinas A. , et al: Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993 ;177:1675—1680.

11.

Tsenova L. , Sokol K. , Freedman VH , Kaplan G. : A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998;177:1563—1572.

12.

Medical Research Council Tuberculosis Trials Committee : Streptomycin treatment of tuberculous meningitis . Lancet 1948;1: 582—596.

13.

Haslett P. , Tramontana J. , Burroughs M. , et al: Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997 ; 24:1223-1227.

14.

Siesjo BK : Pathophysiology and treatment of focal ischemia. Part 1: Pathophysiology. J Neurosurg 1992;77:169—184.

15.

Flynn JL , Goldstein MN , Chan J. , et al: Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.

16.

Mertsola J. , Kennedy WA , Waagner D. , et al: Endotoxin concentrations in cerebrospinal fluid correlate with clinical severity and neurological outcome of Haemophilus influenzae type b meningitis. Am J Dis Child 1991;145:1099—1133.

17.

Haslett PA , Corral LG , Albert M. , Kaplan G. : Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset . J Exp Med 1998;187:1885-1892.